March 12, 2026

BSE Limited **Code: 532321**
P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited **Code: Zyduslife**
Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated March 12, 2026, titled **"Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor Diasens™ and GlucoLive™"**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,
For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.03.12 14:13:37 +05'30'

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor Diasens™ and GlucoLive™

Diasens™ and GlucoLive™ are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care

The next-gen CGM is paired with AI-powered analytics and a dedicated clinician remote-monitoring dashboard which is integrated with GoodFlip™ app designed by TatvaCare™

Ahmedabad, 12 March, 2026

Zydus Lifesciences Limited ("Zydus"), an innovation-led global life sciences company, today announced its new offering companion diagnostics portfolio. The company will be launching Diasens™ and GlucoLive™, next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence-powered insights, and integrated remote care capabilities. The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real time.

Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCare™), a healthcare technology company to help the patients gain access to its proprietary, integrated care ecosystem GoodFlip™ to provide AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab booking, and a comprehensive medical record vault - all in a single mobile application.

Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, "The launch of Diasens™ and GlucoLive™ strengthen our companion diagnostics portfolio for chronic disease management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying monitoring and control. The convergence of science, innovation, health and technology is critical for patients managing chronic diseases like diabetes, CKD, or organ transplant – offering a quick, reliable, and safe glucose monitoring solution with utmost convenience."

India is home to over 101 million adults living with diabetes - the second-highest burden globally - with an additional 136 million in the pre-diabetic stage, according to the ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology. Diabetes is also the leading cause of Chronic Kidney Disease in India, with 25–40% of CKD patients having a diabetes history. An estimated 2,00,000 patients require kidney transplants and 25,000 require liver transplants annually, many of whom develop new-onset diabetes due to immunosuppressive therapies.

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878

Despite this burden, most glucose monitoring in India remains episodic - limited to periodic finger-prick tests or laboratory HbA1c checks every three to six months. Existing CGM devices in the Indian market predominantly rely on NFC technology, requiring patients to manually scan the sensor to retrieve readings. This creates gaps in data continuity, delays clinical intervention, and places the burden of vigilance entirely on the patient.

Diasens™ and GlucoLive™ will enable automatic streaming of glucose readings to the patient's smartphone every three minutes - without manual scanning - ensuring uninterrupted capture, including overnight reading and in emergencies. Through TatvaCare™'s GoodFlip™ app, AI analytics will detect trends, flags hypo-/hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights. A clinician dashboard will support remote monitoring, early intervention, and data-driven treatment adjustments.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com

About Digicare Health Solutions Private Limited (TatvaCare™)

TatvaCare™ is a healthcare technology company advancing care delivery through digital innovation. Focused on connecting the patient care continuum, the company has built an integrated portfolio of solutions, including TatvaPractice™, an advanced EMR platform; Tatva.ai™, a conversational knowledge platform for healthcare professionals; and GoodFlip™, a digital therapeutics application for managing conditions such as fatty liver, diabetes, obesity, COPD, asthma, and breast cancer. Through its technology-led offerings, TatvaCare™ aims to enable more connected, efficient, and patient-centric care across the healthcare ecosystem.

***

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878